• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • What is ALS/MND
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Voice Preservation
      • Open Science
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven (Off-Label) Treatments
      • Open Label Extension
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition and Swallowing
      • Occupational Therapy and Activities of Daily Living
      • Physiotherapy and Mobility
      • Respiratory Care
      • Speech Therapy and Communication
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • AB Science – Masitinib
      • BrainStorm Cell Therapeutics – NurOwn
      • Clene Nanomedicine – CNM-Au8
      • Collaborative Medicinal Development – CuATSM
      • ILB – Tikomed
      • Kadimastem – AstroRx
      • Mitsubishi Tanabe Pharma America – Oral Edaravone
      • Neuronata-R/Lenzumestrocel
      • NeuroSense – PrimeC
      • Neuvivo – NP001
      • Prilenia Therapeutics – Pridopidine
      • T Regulatory Cell Therapies
      • SOD1 Therapies & Trials
    • Approved Drugs
      • Neudexta
      • Radicava/Edaravone
      • Riluzole/Tiglutik
      • Tofersen/Qalsody
    • Drugs No Longer in Development
      • Amylyx – AMX0035
      • Collaborative Medicinal Development – CuATSM
      • Cytokinetics – Reldesemtiv
      • Orphazyme – Arimoclomol
      • TUDCA Trial
  • Support for Health Professionals
    • Breaking the News in ALS/MND
  • Events/Programs
    • Calendar of Events/Programs
    • Alliance Meeting
    • Allied Professionals Forum
    • Alliance Webinars
    • ALS/MND Connect
    • Global Day
    • March of Faces
    • Patient Fellows Program
    • International Symposium
  • About
    • Who We Are
    • Board of Trustees
    • Advisory Councils/Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Innovation and Technology Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Archives
      • Newsletters
      • Meetings
    • Awards
      • Student Innovation Award
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
  • Members
    • Member Registration
    • Forgot Password

Search Results for: rights

Advocacy and Public Policy Forum

…ite 28 European ALS Associations from 22 European countries, defending the rights of all European patients with ALS with emphasis on advocating EU harmonization of access to ALS clinical trials… Continue Reading about Advocacy and Public Policy Forum

SOD1 Therapies & Trials

…024 (Ref: Regeneron JPM 2024 presentation) AviadoBio has recently acquired rights for Neurgian Technologie’s novel approach to deliver gene therapies directly to the spinal cord through a ‘subpial’ injection. This… Continue Reading about SOD1 Therapies & Trials

Genetic Counselling & Testing

…g>GENETICS – COUNSELLING & TESTING The Alliance´s Fundamental Rights were updated in 2021 to include the right to have access upon diagnosis to genetic counselling and testing. There are numerous… Continue Reading about Genetic Counselling & Testing

Asociación ELA Argentina

… Continue Reading about Asociación ELA Argentina

Finance Committee

…ganisation for Professionals and People with ALS (EUpALS), and defends the rights of people living with ALS/MND in scientific advice procedures at the European Medicines Agency (EMA). She is also… Continue Reading about Finance Committee

  • « Go to Previous Page
  • Page 1
  • Page 2
  • Page 3
  • Page 4

Primary Sidebar

Footer

Subscribe to our Bi-Monthly Newsletter

Sign up to receive updates and to hear what's going on in the International Alliance of ALS/MND Associations.

"*" indicates required fields

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2025 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login